US2001041350A1PendingUtilityA1

Human DNA ligase III

57
Assignee: HUMAN GENOME SCIENCES INCPriority: Mar 31, 1995Filed: Jun 13, 2001Published: Nov 15, 2001
Est. expiryMar 31, 2015(expired)· nominal 20-yr term from priority
Inventors:Ying-Fei WeiGuo-Liang YuWilliam A. Haseltine
C12N 9/93A61K 48/00C12N 2799/026
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A human DNA Ligase III polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide via gene therapy for the treatment of disorders associated with a defect in DNA Ligase III. Antagonists against such polypeptides and their use as a therapeutic to destroy unwanted cells are also disclosed. Diagnostic assays to detect mutant DNA Ligase III genes are also disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An antibody or portion thereof that specifically binds to a protein whose sequence consists of an amino acid sequence selected from the group consisting of: 
 (a) amino acids 1 to 922 of SEQ ID NO:2;    (b) amino acids 2 to 922 of SEQ ID NO:2;    (c) an antigenic fragment of the amino acid sequence of SEQ ID NO:2;    (d) amino acids 1 to 922 of SEQ ID NO:2, wherein the amino acid sequence has one to five conservative substitutions;    (e) at least 30 contiguous amino acid residues of SEQ ID NO:2; and    (f) at least 50 contiguous amino acid residues of SEQ ID NO:2.    
     
     
         2 . The antibody or portion thereof of    claim 1   , wherein the amino acid sequence consists of amino acid sequence (a).  
     
     
         3 . The antibody or portion thereof of    claim 1   , wherein the amino acid sequence consists of amino acid sequence (b).  
     
     
         4 . The antibody or portion thereof of    claim 1   , wherein the amino acid sequence consists of amino acid sequence (c).  
     
     
         5 . The antibody or portion thereof of    claim 1   , wherein the amino acid sequence consists of amino acid sequence (d).  
     
     
         6 . The antibody or portion thereof of    claim 1   , wherein the amino acid sequence consists of amino acid sequence (e).  
     
     
         7 . The antibody or portion thereof of    claim 1   , wherein the amino acid sequence consists of amino acid sequence (f).  
     
     
         8 . The antibody or portion thereof of    claim 1    which is a monoclonal antibody.  
     
     
         9 . The antibody or portion thereof of    claim 1    which is a polyclonal antibody.  
     
     
         10 . The antibody or portion thereof of    claim 1    which is a chimeric antibody.  
     
     
         11 . The antibody or portion thereof of    claim 1    which is a humanized antibody.  
     
     
         12 . The antibody or portion thereof of    claim 1    which is a single chain antibody.  
     
     
         13 . The antibody or portion thereof of    claim 1    which is an Fab fragment.  
     
     
         14 . A pharmaceutical composition comprising the antibody or portion thereof of    claim 1    and a pharmaceutically acceptable carrier.  
     
     
         15 . The pharmaceutical composition of    claim 14   , wherein the antibody or portion thereof is a monoclonal antibody.  
     
     
         16 . The pharmaceutical composition of    claim 14   , wherein the antibody or portion thereof is a polyclonal antibody.  
     
     
         17 . The pharmaceutical composition of    claim 14   , wherein the antibody or portion thereof is a chimeric antibody.  
     
     
         18 . The pharmaceutical composition of    claim 14   , wherein the antibody or portion thereof is a humanized antibody.  
     
     
         19 . The pharmaceutical composition of    claim 14   , wherein the antibody or portion thereof is a single chain antibody.  
     
     
         20 . The pharmaceutical composition of    claim 14   , wherein the antibody or portion thereof is an Fab fragment.  
     
     
         21 . The pharmaceutical composition of    claim 14   , wherein the antibody or portion thereof is a humanized monoclonal antibody.  
     
     
         22 . A hybridoma cell line that produces a monoclonal antibody or portion thereof that specifically binds to a protein whose sequence consists of an amino acid sequence selected from the group consisting of: 
 (a) amino acids 1 to 922 of SEQ ID NO:2;    (b) amino acids 2 to 922 of SEQ ID NO:2;    (c) an antigenic fragment of the amino acid sequence of SEQ ID NO:2;    (d) amino acids 1 to 922 of SEQ ID NO:2, wherein the amino acid sequence has one to five conservative substitutions;    (e) at least 30 contiguous amino acid residues of SEQ ID NO:2; and    (f) at least 50 contiguous amino acid residues of SEQ ID NO:2.    
     
     
         23 . The hybridoma cell line of    claim 22   , wherein the antibody or portion thereof is humanized.  
     
     
         24 . An antibody or portion thereof produced by immunizing an animal with a protein whose sequence consists of an amino acid sequence selected from the group consisting of: 
 (a) amino acids 1 to 922 of SEQ ID NO:2;    (b) amino acids 2 to 922 of SEQ ID NO:2;    (c) an antigenic fragment of the amino acid sequence of SEQ ID NO:2;    (d) amino acids 1 to 922 of SEQ ID NO:2, wherein the amino acid sequence has one to five conservative substitutions;    (e) at least 30 contiguous amino acid residues of SEQ ID NO:2; and    (f) at least 50 contiguous amino acid residues of SEQ ID NO:2;    wherein said antibody or portion thereof specifically binds to said protein.    
     
     
         25 . An antibody or portion thereof that specifically binds to a protein whose sequence consists of an amino acid sequence selected from the group consisting of: 
 (a) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052;    (b) the full-length protein, excluding the N-terminal methionine, encoded by the human cDNA contained in ATCC Deposit No. 97052;    (c) a mature protein encoded by the human cDNA contained in ATCC Deposit No. 97052;    (d) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052, wherein the amino acid sequence has one to five conservative substitutions;    (e) an antigenic fragment of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052;    (f) at least 30 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052; and    (g) at least 50 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052.    
     
     
         26 . The antibody or portion thereof of    claim 25   , wherein the amino acid sequence consists of amino acid sequence (a).  
     
     
         27 . The antibody or portion thereof of    claim 25   , wherein the amino acid sequence consists of amino acid sequence (b).  
     
     
         28 . The antibody or portion thereof of    claim 25   , wherein the amino acid sequence consists of amino acid sequence (c).  
     
     
         29 . The antibody or portion thereof of    claim 25   , wherein the amino acid sequence consists of amino acid sequence (d).  
     
     
         30 . The antibody or portion thereof of    claim 25   , wherein the amino acid sequence consists of amino acid sequence (e).  
     
     
         31 . The antibody or portion thereof of    claim 25   , wherein the amino acid sequence consists of amino acid sequence (f).  
     
     
         32 . The antibody or portion thereof of    claim 25   , wherein the amino acid sequence consists of amino acid sequence (g).  
     
     
         33 . The antibody or portion thereof of    claim 25    which is a monoclonal antibody.  
     
     
         34 . The antibody or portion thereof of    claim 25    which is a polyclonal antibody.  
     
     
         35 . The antibody or portion thereof of    claim 25    which is a chimeric antibody.  
     
     
         36 . The antibody or portion thereof of    claim 25    which is a humanized antibody.  
     
     
         37 . The antibody or portion thereof of    claim 25    which is a single chain antibody.  
     
     
         38 . The antibody or portion thereof of    claim 25    which is an Fab fragment.  
     
     
         39 . A pharmaceutical composition comprising the antibody or portion thereof of    claim 25    and a pharmaceutically acceptable carrier.  
     
     
         40 . The pharmaceutical composition of    claim 39   , wherein the antibody or portion thereof is a monoclonal antibody.  
     
     
         41 . The pharmaceutical composition of    claim 39   , wherein the antibody or portion thereof is a polyclonal antibody.  
     
     
         42 . The pharmaceutical composition of    claim 39   , wherein the antibody or portion thereof is a chimeric antibody.  
     
     
         43 . The pharmaceutical composition of    claim 39   , wherein the antibody or portion thereof is a humanized antibody.  
     
     
         44 . The pharmaceutical composition of    claim 39   , wherein the antibody or portion thereof is a single chain antibody.  
     
     
         45 . The pharmaceutical composition of    claim 39   , wherein the antibody or portion thereof is an Fab fragment.  
     
     
         46 . The pharmaceutical composition of    claim 39   , wherein the antibody or portion thereof is a humanized monoclonal antibody.  
     
     
         47 . A hybridoma cell line that produces a monoclonal antibody or portion thereof that specifically binds to a protein whose sequence consists of an amino acid sequence selected from the group consisting of: 
 (a) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052;    (b) the full-length protein, excluding the N-terminal methionine, encoded by the human cDNA contained in ATCC Deposit No. 97052;    (c) a mature protein encoded by the human cDNA contained in ATCC Deposit No. 97052;    (d) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052, wherein the amino acid sequence has one to five conservative substitutions;    (e) an antigenic fragment of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052;    (f) at least 30 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052; and    (g) at least 50 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052.    
     
     
         48 . The hybridoma cell line of    claim 47   , wherein the antibody or portion thereof is humanized.  
     
     
         49 . An antibody or portion thereof produced by immunizing an animal with a protein whose sequence consists of an amino acid sequence selected from the group consisting of: 
 (a) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052;    (b) the full-length protein, excluding the N-terminal methionine, encoded by the human cDNA contained in ATCC Deposit No. 97052;    (c) a mature protein encoded by the human cDNA contained in ATCC Deposit No. 97052;    (d) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052, wherein the amino acid sequence has one to five conservative substitutions;    (e) an antigenic fragment of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052;    (f) at least 30 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052; and    (g) at least 50 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052;    wherein said antibody or portion thereof specifically binds to said protein.

Join the waitlist — get patent alerts

Track US2001041350A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.